nach oben

Erschienen in:

01.11.2013 | Original article

Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma

Hypotheses based on two prospective phase II trials

verfasst von: M. Balducci, A. Fiorentino, MD, P. De Bonis, S. Chiesa, A. Mangiola, G.C. Mattiucci, G.R. D’Agostino, V. Frascino, G. Mantini, A.R. Alitto, C. Colosimo, C. Anile, V. Valentini

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Aim

To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM).

Patients and methods

From October 2000 to June 2008, 104 patients were enrolled in two studies: 25 in RT-TMZ-10.00 and 79 in RT-TMZ-01.04. Adjuvant radiotherapy (RT) was used with a total dose of 59.4 Gy (1.8 Gy/day). Patients received concomitant TMZ (75 mg/m²/day) from Monday to Friday during the first and last weeks of RT in the RT-TMZ-10.00 study and from Monday to Friday during all weeks of RT in the RT-TMZ-01.04 trial. Adjuvant TMZ (200 mg/m²) was administered for 5 days every 28 days.

Results

Median progression-free (PFS) and overall survival (OS) were 9 and 16 months, respectively, with no significant difference between the two groups (p = 0.5 and 0.14, respectively). The 2- and 5-year OS rates were 32 and 3 %, respectively, and similar to those observed with standard treatment regimens.

Conclusion

Our data support the hypothesis that adjuvant TMZ is more important than concomitant chemotherapy (CH) and that RT is the more important element of the concomitant treatment schedule.

Asthagiri AR, Pouratian N, Sherman J et al (2007) Advances in brain tumor surgery. Neurol Clin 25:975–1003PubMedCrossRef

Athanassiou H, Sinodinou M, Maragoudakis E et al (2005) Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23(10):2372–2377PubMedCrossRef

Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase ii study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high grade gliomas. Strahlenther Onkol 186(10):558–564PubMedCrossRef

Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14(1):79–86PubMedCrossRef

Balducci M, D’Agostino GR, Manfrida S et al (2010) Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neuroncol 97(1):95–100CrossRef

Beauchesne P, Bernier V, Carnin C et al (2010) Prolonged survival for patients with newly diagnosed, inoperable gliobastoma with 3-times daily ultra fractionated radiation therapy. Neuro Oncol 12(6):595–602PubMedCrossRef

Chalmers AJ, Ruff EM, Martindale C et al (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 75(5):1511–1519PubMedCrossRef

Combs SE, Wagner J, Bischof M et al (2008) Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71:999–1005PubMedCrossRef

Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive portioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRef

10.

Fiorentino A, Caivano R, Pedicini P, Fusco V (2013) Clinical target volume definition for glioblastoma treatment planning: magnetic resonance imaging and computed tomography. Clin Transl Oncol doi:10.1007/s12094-012-0992-y

11.

Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed

12.

Hainsworth JD, Ervin T, Friedman E et al (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15):3663–3669PubMedCrossRef

13.

Hirose Y, Berger MS, Pieper RO (2001) P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963PubMed

14.

Kesari S, Advani SJ, Lawson JD et al (2011) DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol 7(11):1335–1346PubMedCrossRef

15.

Kocher M, Frommolt P, Borberg SK et al (2008) Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 184:572–579PubMedCrossRef

16.

Kocher M, Kunze S, Eich HT et al (2005) Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 181:157–163PubMedCrossRef

17.

Lanzetta G, Campanella C, Rozzi A et al (2003) Temozolomide in radio-chemotherapy combined treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164PubMed

18.

Mancuso S, Smaniotto D, Benedetti-Panici PL et al (2000) Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 78:324–328PubMedCrossRef

19.

Morganti AG, Balducci M, Salvati M et al (2010) A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys 77(1):92–97PubMedCrossRef

20.

RoldanUgoiti GB, Singh AD, Easaw JC (2012) Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma. J Neuroncol 108(1):173–177CrossRef

21.

Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239–244PubMedCrossRef

22.

Sridhar T, Gore A, Boiangiu I et al (2009) Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. Clin Oncol (R Coll Radiol) 21:19–22

23.

Steward LA (2002) Chemotherapy in adult high grade glioma: a systematic review and metanalysis of individual patient data from 12 randomized trials. Lancet 359:1011–1018CrossRef

24.

Stupp R, Hegi ME, Gilbert MR, Charkravarti A (2007) Chemo-radiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25(26):4127–4136PubMedCrossRef

25.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef

26.

Stupp R, Mason WP, Van der Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblatoma. N Engl J Med 352(10):987–996PubMedCrossRef

27.

Valentini V, Coco C, Cellini N et al (1999) Preoperative chemoradiation with cisplatin and 5-fluorouracil for extra peritoneal T3 rectal cancer: acute toxicity tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 45:1175–1184PubMedCrossRef

28.

Wedge SR, Porteous JK, Glaser MG et al (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92–97PubMedCrossRef

Titel: Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma
Hypotheses based on two prospective phase II trials
verfasst von: M. Balducci
A. Fiorentino, MD
P. De Bonis
S. Chiesa
A. Mangiola
G.C. Mattiucci
G.R. D’Agostino
V. Frascino
G. Mantini
A.R. Alitto
C. Colosimo
C. Anile
V. Valentini
Publikationsdatum: 01.11.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0410-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma

Hypotheses based on two prospective phase II trials

Abstract